TTMI's RF and Mission Systems Shift Boosts Margins: What's Ahead?
TTM Technologies capitalizes on rising AI workloads and defense spending, boosting interconnect dema…

| Indicator | Value | Signal | Strength |
|---|---|---|---|
| RSI (14) | 48.4 | —NEUTRAL | 3% |
| SMA 50↓ RES | $85.61 | ▼BEARISH | 0% |
| SMA 200↓ RES | $88.23 | ▼BEARISH | 0% |
| EMA 50 | $85.04 | ▼BEARISH | 0% |
| EMA 200 | $88.21 | ▼BEARISH | 0% |
| MA Trend | 50D < 200D | ▼DEATH X | 41% |
| MACD | -1.34 | ▼BEARISH | 43% |
Momentum neutral-to-bearish
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $1.5B $1.5B–$1.5B | — | $3.75 | — | ±1% | High9 |
FY2026(current) | $1.6B $1.6B–$1.6B | ▲ +7.1% | $4.03 | ▲ +7.6% | ±1% | High6 |
FY2027 | $1.7B $1.7B–$1.7B | ▲ +6.1% | $4.40 | ▲ +9.0% | ±2% | High6 |
merit medical systems, inc. (nasdaq: mmsi) is a leading manufacturer of medical devices used in diagnostic & interventional cardiology & radiology procedures. its primary products consist of inflation devices used in angioplasty, stent placement & discography; diagnostic & therapeutic catheters used for various procedures in cardiology & radiology; guide wires used to place balloon angioplasty catheters within a patient's coronary arteries; products used to manage & monitor the administration of contrast & other fluid solutions during diagnostic & therapeutic procedures; thrombolytic catheters & fluid dispensing systems; angiography accessories; & standard & custom angiography kits. headquartered in south jordan, utah, a suburb of salt lake city, merit employs approximately 1,900 people worldwide. merit markets its products in the united states & europe (direct sales force) & the world (distributors). they call directly on physicians & clinicians in hospitals & clinics worldwide. the c
TTM Technologies capitalizes on rising AI workloads and defense spending, boosting interconnect dema…

Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
MMSI◀ | $67.75 | -0.04% | $4.1B | 31.7 | +1175.0% | 847.6% | 1500 |
| $75.94 | +0.00% | $14.2B | — | — | — | 1500 | |
| $522.68 | +0.00% | $11.8B | — | — | — | 1500 | |
| $89.89 | +0.00% | $11.7B | — | — | — | 1500 | |
| $191.20 | +0.00% | $11.0B | — | — | — | 1500 | |
| $74.08 | +0.00% | $10.3B | — | +2325815.3% | — | 1500 | |
| $192.88 | +0.00% | $9.5B | — | — | — | 1500 | |
| Sector avg | — | -0.01% | — | 31.7 | +1163495.1% | 847.6% | 1500 |
US interventional procedure volumes - particularly cardiac catheterizations, peripheral vascular interventions, and interventional oncology procedures which drive device utilization
New product launch momentum and market share gains in embolization (competing with Boston Scientific, Terumo) and hemostasis (competing with Teleflex, Terumo)
Gross margin trajectory driven by manufacturing efficiency, product mix shift toward higher-margin embolization/oncology devices, and raw material cost inflation
International revenue growth, particularly in Europe and Asia-Pacific where distributor partnerships and direct expansion drive penetration
moderate - Interventional procedures are semi-discretionary with 60-70% driven by urgent/emergent cases (STEMI, stroke, cancer) that are recession-resistant, but 30-40% are elective procedures (stable angina, peripheral claudication) that can be deferred during economic stress. Hospital capital budgets and staffing levels also affect procedure scheduling capacity. GDP growth correlates with elective procedure volumes and hospital purchasing patterns, but the relationship is dampened by aging demographics (Medicare-driven demand) and clinical guideline expansion favoring minimally invasive techniques.
Rising rates have modest negative impact through two channels: (1) higher borrowing costs on $250M+ debt balance (mix of fixed/variable), though Debt/Equity of 0.57 is manageable, and (2) valuation multiple compression as med-tech stocks typically trade on forward P/E and rising discount rates reduce present value of future earnings. Demand side is largely insulated as procedures are reimbursed by Medicare/commercial insurance, not consumer-financed. Hospital system capital spending can be constrained by higher financing costs, but Merit's consumables model is less affected than capital equipment vendors.
Reimbursement pressure from CMS and commercial payers reducing procedure payments, which forces hospitals to demand lower device pricing and threatens gross margins
Regulatory pathway changes - FDA increased scrutiny of 510(k) clearances or reclassification of devices to PMA standard would slow new product launches and increase development costs
Shift toward value-based care and bundled payments incentivizes hospitals to consolidate vendors and negotiate aggressive pricing, benefiting larger competitors (Medtronic, Boston Scientific) with broader portfolios
value - Stock trades at 2.8x P/S and 14.4x EV/EBITDA, below historical medtech averages, attracting value investors betting on margin expansion and multiple re-rating. Recent 27% one-year decline creates contrarian opportunity if procedural volumes stabilize and operational execution improves. 5% FCF yield provides downside support. Growth investors are less attracted given single-digit EPS growth, but improving organic growth and M&A could shift sentiment.